Cover Image

Activation of FcRn Mediates a Primary Resistance Response to Sorafenib in Hepatocellular Carcinoma by Single-Cell RNA Sequencing

Sorafenib is the first-line therapeutic option for advanced hepatocellular carcinoma (HCC). Many patients exhibit a primary resistance (PR) response after initial treatment. In previous studies, compared to acquired resistance, the mechanism of PR is unclear. The present study aimed to evaluate the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xin Guan (Author), Yi Wu (Author), Shuqin Zhang (Author), Zhiyi Liu (Author), Qingjie Fan (Author), Shuai Fang (Author), Sennan Qiao (Author), Fei Sun (Author), Chongyang Liang (Author)
Format:	Book
Published:	Frontiers Media S.A., 2021-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Selection of bispecific antibodies with optimal developability using FcRn‑pH‑HPLC as an optimized FcRn affinity chromatography method
by: Thomas Müller, et al.
Published: (2023)

Efgartigimod, an FcRn antagonist, as a potential treatment for post COVID-19 syndrome
by: Sandra E. Reznik, et al.
Published: (2023)

The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein
by: Takuo Suzuki, et al.
Published: (2021)

Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro
by: Omar S. Qureshi, et al.
Published: (2024)

Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models
by: Delphine Valente, et al.
Published: (2020)

Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia
by: Trang T. Vu, et al.
Published: (2024)

Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier
by: Jason Tien, et al.
Published: (2023)

The contribution of cell surface FcRn in monoclonal antibody serum uptake from the intestine in suckling rat pups
by: Philip R Cooper, et al.
Published: (2014)

Insight into the avidity-affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn
by: Johannes Reusch, et al.
Published: (2024)

Pharmacokinetic‐pharmacodynamic modelling of the anti‐FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic
by: Rocio Lledo‐Garcia, et al.
Published: (2022)

Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis
by: Jeffrey T. Guptill, et al.
Published: (2022)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers
by: Desmond Y. H. Yap, et al.
Published: (2021)

FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaques
by: Joanna Zikos, et al.
Published: (2024)

Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
by: Simone Mester, et al.
Published: (2021)

TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma
by: Ying Wu, et al.
Published: (2020)

Synthesis and anti-hepatocellular carcinoma activity of aminopyridinol-sorafenib hybrids
by: Bhuwan Prasad Awasthi, et al.
Published: (2021)

Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma
by: Koen G. A. M. Hussaarts, et al.
Published: (2021)

Enhanced anti-tumor therapy for hepatocellular carcinoma via sorafenib and KIAA1199-siRNA co-delivery liposomes
by: Yao Yao, et al.
Published: (2024)

Exacerbation of psoriasis with pustulation by sorafenib in a patient with metastatic hepatocellular carcinoma
by: Takenobu Ohashi, et al.
Published: (2019)

Atypical targetoid eruption induced by sorafenib in a patient with hepatocellular carcinoma
by: Pinar Incel Uysal, et al.
Published: (2020)

Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights
by: Xinchen Tian, et al.
Published: (2022)

Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma
by: Liu KC, et al.
Published: (2020)

Synthesis, characterization, and antiproliferative evaluation of novel sorafenib analogs for the treatment of hepatocellular carcinoma
by: Marwan Imad Jihad, et al.
Published: (2023)

Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways
by: Haofeng Lu, et al.
Published: (2022)

Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma
by: Can G. Leineweber, et al.
Published: (2023)

Whole genome and RNA sequencing analyses for 254 Taiwanese hepatocellular carcinomas
by: Ya-Sian Chang, et al.
Published: (2023)

GSTA1/CTNNB1 axis facilitates sorafenib resistance via suppressing ferroptosis in hepatocellular carcinoma
by: Shiwen Ma, et al.
Published: (2024)

Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study
by: John C. Panetta, et al.
Published: (2021)

FOXM1-Mediated LINC-ROR Regulates the Proliferation and Sensitivity to Sorafenib in Hepatocellular Carcinoma
by: Yingru Zhi, et al.
Published: (2019)

Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma
by: Can G. Leineweber, et al.
Published: (2024)

Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma
by: Shun Zhang, et al.
Published: (2022)

Efficacy and Safety of Sorafenib Versus Supportive Care in Egyptian Advanced Hepatocellular Carcinoma Patients
by: Noha Salah El Baghdady, et al.
Published: (2020)

Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study
by: Min Zhang, et al.
Published: (2024)

Therapeutic Effects of Crocin Alone or in Combination with Sorafenib against Hepatocellular Carcinoma: In Vivo & In Vitro Insights
by: Suzan Abdu, et al.
Published: (2022)

In vivo inhibitory effect of suberoylanilide hydroxamic acid combined with sorafenib on human hepatocellular carcinoma cells
by: Dalin Hao, et al.
Published: (2020)

Augmented Efficacy of Uttroside B over Sorafenib in a Murine Model of Human Hepatocellular Carcinoma
by: Mundanattu Swetha, et al.
Published: (2022)

Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma
by: Yawen Yao, et al.
Published: (2024)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
by: Ye Peng, et al.
Published: (2022)

KSR2-14-3-3ζ complex serves as a biomarker and potential therapeutic target in sorafenib-resistant hepatocellular carcinoma
by: Chao Gao, et al.
Published: (2022)

Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
by: Yan Li, et al.
Published: (2022)